Non Small Cell Lung Cancer Clinical Trials in Cincinnati, Ohio

19 studies are recruiting for non small cell lung cancer in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Cincinnati, Ohio
    Locations
    328 in total
    Run by
    AstraZeneca

    See if you can join NCT06692738 on ClinicalTrials.gov

  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Study Sites, Cincinnati, Ohio
    Locations
    285 in total
    Run by
    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

  3. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

    Stage
    Not phased
    Ages
    18 and older
    Site
    The Christ Hospital Cancer Center, Cincinnati, Ohio
    Locations
    57 in total
    Run by
    Guardant Health, Inc.

    See if you can join NCT05059444 on ClinicalTrials.gov

  4. Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati, Ohio
    Locations
    61 in total
    Run by
    AbbVie

    See if you can join NCT06236438 on ClinicalTrials.gov

  5. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

    The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Christ Hospital, Cincinnati, Ohio
    Locations
    29 in total
    Run by
    Tubulis GmbH

    See if you can join NCT06303505 on ClinicalTrials.gov

  6. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

    The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Cincinnati Medical Center, Cincinnati, Ohio
    Locations
    326 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT06561386 on ClinicalTrials.gov

  7. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati, Ohio
    Locations
    225 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06345729 on ClinicalTrials.gov

  8. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

    This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The Christ Hospital Cancer Center, Cincinnati, Ohio
    Locations
    262 in total
    Run by
    BioNTech SE

    See if you can join NCT06712316 on ClinicalTrials.gov

  9. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    TriHealth Cancer & Blood Institute Research, Cincinnati, Ohio
    Locations
    153 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06881784 on ClinicalTrials.gov

  10. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

    Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Cincinnati Cancer Center, Cincinnati, Ohio
    Locations
    158 in total
    Run by
    Nuvalent Inc.

    See if you can join NCT06765109 on ClinicalTrials.gov

  11. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

    This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Oncology Hematology Care (OHC), Inc, Cincinnati, Ohio
    Locations
    260 in total
    Run by
    Summit Therapeutics

    See if you can join NCT05899608 on ClinicalTrials.gov

  12. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio
    Locations
    52 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06586515 on ClinicalTrials.gov

  13. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

    The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0028), Cincinnati, Ohio
    Locations
    229 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06077760 on ClinicalTrials.gov

  14. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Oncology Hematology Care Clinical Trials, Cincinnati, Ohio
    Locations
    440 in total
    Run by
    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

  15. Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Cincinnati, Ohio
    Locations
    287 in total
    Run by
    AstraZeneca

    See if you can join NCT06357533 on ClinicalTrials.gov

  16. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Cincinnati, Cincinnati, Ohio
    Locations
    50 in total
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT02468024 on ClinicalTrials.gov

  17. Promoting Immunotherapy Efficacy With Low-Dose Liver RT

    The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Cincinnati Medical Center, Cincinnati, Ohio
    Run by
    Jordan Kharofa

    See if you can join NCT07225036 on ClinicalTrials.gov

  18. GEMINI-NSCLC: NSCLC Biomarker Study

    GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

    Stage
    Not phased
    Ages
    18 and older
    Site
    TriHealth Cancer Institute, Cincinnati, Ohio
    Locations
    58 in total
    Run by
    Tempus AI

    See if you can join NCT05236114 on ClinicalTrials.gov

  19. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Cincinnati, Ohio
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.